Developer docs
API playgroundTry for free, no card

Search company profiles

Mucinex

Full company profile

uuid0007at2

Namestring
Mucinex
Legal namestring
RB Health (US) LLC
Websiteurl
mucinex.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Mucinex is an over-the-counter consumer health brand specializing in cold, flu, sinus, and chest congestion relief, founded in 2003 and operated by RB Health (US) LLC, a subsidiary of UK-listed Reckitt. The brand is headquartered in Parsippany, New Jersey, and serves general adult consumers, children, healthcare providers, and (since late 2025) Canadian consumers. The product portfolio spans extended-release bi-layer tablets containing guaifenesin (and dextromethorphan/phenylephrine variants in the DM and D lines), Fast-Max liquid gels and caplets for multi-symptom cold/flu relief, Sinus-Max nasal sprays with proprietary POWER-JET and GENTLE-MIST 2-in-1 nozzle technologies, Nightshift formulations for nighttime symptom relief, Rapid Clear caplets, and pediatric formulations under the Children's line, plus the recently launched Clear & Cool Saline Nasal Spray.

Mucinex's core technological differentiator is its extended-release bi-layer tablet platform, which delivers 12 hours of symptom relief per dose, roughly double the dosing interval of most generic competitors. The brand also maintains a significant clinical evidence base, including long-term findings from the GASP Study demonstrating efficacy of extended-release guaifenesin over 12 weeks in patients with stable chronic bronchitis. The brand has been supported for over two decades by the distinctive Mr. Mucus mascot, which functions as the principal intangible asset underpinning consumer recognition.

The business model is a classic OTC consumer health model: one-time retail purchases through mass retail distribution (pharmacies, grocery, mass merchants) in the US and Canada, supplemented by direct-to-consumer e-commerce via mucinex.com. Products are HSA/FSA eligible. The brand does not disclose its revenue separately; financial results are consolidated within Reckitt's Health segment. Marketing relies on a multi-channel approach including social media (Facebook, Instagram, YouTube), content marketing via a Tips & Resources learning center, public relations, and high-visibility experiential campaigns (e.g., the 2025 AR-enhanced 3D art installation at Grand Central Terminal with artist Kurt Wenner).

Short descriptiontext

Mucinex is a US OTC consumer health brand owned by Reckitt, providing 12-hour extended-release cold, flu, sinus, and chest congestion relief products for general adults, children, and now Canadian consumers, distributed through major retailers and direct e-commerce.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
OTC cold and flu remedies, extended-release expectorant tablets, nasal decongestant sprays, pediatric cough medications, sore throat relief products
Industry4 codes
PRIMARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYHLAIADAB
Cold, Flu & Cough Remedies
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAL
Pediatric OTC Medicines
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • Soap and Cleaning Compound Manufacturing32561
Product category
OTC Cold, Flu & Sinus Medications
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1OTC Pharmaceutical Products
TypeOne Time License
Description

Mucinex generates revenue through the sale of over-the-counter cold, flu, and sinus relief medications including extended-release tablets, liquid gels, caplets, and nasal sprays. Products are sold as one-time purchases through retail partners and direct-to-consumer e-commerce channels. HSA/FSA eligible expenses.

mucinex.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Marketing or Sales, Supply Chain, Technology or R&D, Personnel
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Fast-Max
Description

Line of fast-acting liquid and gel cold and flu relief products

mucinex.com
+5 more records
Core offering1 text field

Mucinex manufactures and sells over-the-counter cold, flu, sinus, cough, and sore throat medications for adults and children under the Mucinex brand umbrella. Its core technology is a 12-hour extended-release bi-layer tablet (guaifenesin-based), complemented by fast-acting liquid gels, caplets, nasal sprays with POWER-JET and GENTLE-MIST nozzle systems, and pediatric formulations. Products are sold as one-time purchases in retail stores and direct-to-consumer e-commerce.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 12-hour symptom relief duration from extended-release formulations
+2 more records
Product overview1 text field

Mucinex is an over-the-counter (OTC) cold, flu, and sinus relief brand owned by Reckitt. The product portfolio is structured as a multi-format platform approach, offering medications in extended-release bi-layer tablets, fast-acting liquid gels/caplets, nasal sprays, and children's formulations. The core products include Mucinex Extended-Release Bi-Layer Tablets (the original guaifenesin-based chest congestion product), the Fast-Max line (liquids and caplets for multi-symptom cold and flu), Sinus-Max products (targeting sinus and nasal congestion including Clear & Cool nasal sprays), Nightshift formulations (specialized nighttime products for sleep-friendly symptom relief), Rapid Clear (rapid-release caplets), and children's variants. The products work together as a comprehensive symptom management system covering cough, chest congestion, sinus/nasal congestion, cold, flu, sore throat, and pain symptoms across different age groups and symptom severities.

Product and service13 records
1Mucinex Extended-Release Bi-Layer Tablets
CategoryCough & Chest Congestion
Description

Extended-release bi-layer tablets containing guaifenesin for chest congestion relief. Provides 12-hour symptom relief by thinning and loosening mucus in the airways. Targeted at adults with chest congestion.

2Mucinex DM Extended-Release Bi-Layer Tablets
CategoryCough & Chest Congestion
Description

Extended-release bi-layer tablets combining guaifenesin (expectorant) and dextromethorphan (cough suppressant) for chest congestion and cough relief over 12 hours. Targeted at adults with cough and chest congestion.

3Maximum Strength Mucinex DM Extended-Release Bi-Layer Tablets
CategoryCough & Chest Congestion
Description

Maximum strength version of extended-release bi-layer tablets combining guaifenesin and dextromethorphan for severe chest congestion and cough, providing 12-hour relief. Targeted at adults with severe cough and congestion.

4Mucinex Fast-Max Liquid Products
CategoryCold & Flu
Description

Fast-acting liquid and liquid gel formulations for multi-symptom cold and flu relief. Includes Day and Night formulas, severe cold variants, and combination packs. Targeted at adults needing multi-symptom cold and flu relief.

5Mucinex Fast-Max Caplets
CategoryCold & Flu
Description

Rapid-release caplet formulations for cold, flu, and congestion symptoms. Includes Day Cold & Flu, Night Cold & Flu, Severe Congestion & Cough, and Cold, Flu & Sore Throat variants. Targeted at adults with multi-symptom cold and flu.

6Mucinex Sinus-Max Products
CategorySinus & Nasal Congestion
Description

Product line specifically targeting sinus symptoms including nasal sprays, liquid gels, caplets, and combination day/night packs. Includes Clear & Cool nasal spray with menthol cooling sensation. Targeted at adults with sinus and nasal congestion.

7Sinus-Max Severe Nasal Congestion Relief Clear & Cool
CategorySinus & Nasal Congestion
Description

Nasal decongestant spray with oxymetazoline hydrochloride (0.05%) providing up to 12 hours of relief with a cooling menthol flavor. Fast-acting for day and night use. Targeted at adults with severe nasal congestion.

8Mucinex Sinus-Max Saline Nasal Spray
CategorySinus & Nasal Congestion
Description

Drug-free saline nasal spray with 2-in-1 nozzle technology featuring POWER-JET for tough congestion (ages 6+) and GENTLE-MIST for everyday use (ages 2+). Targeted at adults and children with everyday nasal congestion.

9Mucinex Sinus Clear & Cool Saline Nasal Spray
CategorySinus & Nasal Congestion
Description

Saline nasal spray with instant cooling sensation for congestion relief. Features dual spray settings — POWER-JET for tough congestion (ages 12+) and GENTLE-MIST for everyday use. Targeted at adults and older children with congestion seeking drug-free relief.

10Mucinex Nightshift Products
CategoryCold & Flu
Description

Nighttime-specific formulations for cold, flu, and sinus symptoms. Includes Nightshift Cold & Flu (liquid and caplets), Nightshift Sinus, and Nightshift Severe Cold & Flu variants. Designed to help users sleep and wake up feeling better. Targeted at adults whose symptoms disrupt sleep.

11Mucinex Rapid Clear Products
CategoryPain Congestion
Description

Rapid-release caplet line for fast symptom relief. Includes DayTime (Pain, Headache & Mucus Congestion) and NightTime (Headache, Cough & Fever) formulations, plus combination packs. Targeted at adults needing fast-acting relief.

12Mucinex Children's Products
CategoryChildren's Products
Description

Product line formulated for children including liquids, mini-melts, chewable tablets, and multi-symptom cold & flu formulations. Available in flavors such as Very Berry, Cherry, Mixed Berry, and Orange Creme. Targeted at parents/caregivers treating pediatric cough, congestion, and cold symptoms.

13Mucinex InstaSoothe Products
CategorySore Throat
Description

Sore throat relief line including Kickstart Sore Throat Spray (Winterfresh flavor), Sore Throat + Cough Relief, Sore Throat + Pain Relief (drops and spray), Soothing Comfort, and Sugar-Free Cough Drops (Mixed Berry). Targeted at adults with sore throat and cough symptoms.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Kurt Wenner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Mucinex partnered with artist Kurt Wenner to create an experiential 3D art exhibit at Grand Central Terminal (December 1-7, 2025). The glacier-inspired installation promoted the new Clear & Cool Sinus Nasal Spray with interactive AR elements, visually representing the product's cooling relief benefit.

prnewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Robitussin
TypeDirect peer
Description

Robitussin (Haleon) is a direct OTC competitor offering cough, chest congestion, and multi-symptom cold/flu products (including DM formulations) targeting the same adult self-medication occasions as Mucinex's DM and Maximum Strength SKUs.

TypeDirect peer
Description

Tylenol Cold & Flu (Kenvue / Johnson & Johnson) is a direct competitor in cold/flu multi-symptom relief, anchored by acetaminophen-based formulations. Tylenol's household-name brand and similar SKU structure make it one of Mucinex's closest OTC rivals on shelf.

3Alka-Seltzer Plus
TypeDirect peer
Description

Alka-Seltzer Plus (Bayer) is a direct competitor offering effervescent and cold/flu multi-symptom formulations, addressing the same self-medication use cases and competing for the same cold/flu shelf space as Mucinex's Fast-Max line.

TypeEmerging player
Description

Benadryl (Kenvue) competes in adjacent OTC allergy/sinus categories that overlap with Mucinex's Sinus-Max line and overlap consumer occasions for multi-symptom relief, though Benadryl's core franchise is antihistamine-driven rather than expectorant.

TypeDirect peer
Description

Sudafed (Kenvue) competes directly with Mucinex's Sinus-Max decongestant and pressure/pain SKUs in the nasal and sinus congestion category, using pseudoephedrine/phenylephrine-based formulations targeting the same adult consumer.

6DayQuil / NyQuil
TypeDirect peer
Description

DayQuil and NyQuil (Procter & Gamble / Vicks franchise) are direct day/night multi-symptom cold and flu competitors. They share the same shelf positioning, retail channels, and adult consumer occasions as Mucinex's Fast-Max and Nightshift product lines.

TypeBroad incumbent
Description

Kenvue (spun out of Johnson & Johnson) owns Tylenol, Sudafed, Benadryl, Zyrtec, and Nicorette — a portfolio that directly overlaps Mucinex's cold/flu/sinus/allergy categories and competes for the same shelf, retailer relationships, and consumer occasions at global scale.

TypeBroad incumbent
Description

Haleon is a global consumer health platform that owns Robitussin, Theraflu, Advil, Centrum, and Sensodyne, giving it broad OTC reach that includes direct Mucinex competitors. As Reckitt's closest peer in consumer health scale, Haleon represents the strategic benchmark for portfolio breadth and international reach.

TypeDirect peer
Description

Theraflu (Haleon) targets multi-symptom cold and flu relief through powdered and liquid formulations, directly competing with Mucinex Fast-Max in the same adult self-medication segment and same retail OTC shelves.

TypeDirect peer
Description

Vicks (Procter & Gamble) competes across cough, cold, and sinus categories with VapoRub, NyQuil/DayQuil, and Sinex nasal sprays — overlapping Mucinex's chest congestion, multi-symptom, and sinus nasal spray lines with similar retail placement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mucinex

OTC Cold, Flu & Sinus Medicationsmucinex.com

Mucinex is a US OTC consumer health brand owned by Reckitt, providing 12-hour extended-release cold, flu, sinus, and chest congestion relief products for general adults, children, and now Canadian consumers, distributed through major retailers and direct e-commerce.

What Mucinex does

Mucinex is an over-the-counter consumer health brand specializing in cold, flu, sinus, and chest congestion relief, founded in 2003 and operated by RB Health (US) LLC, a subsidiary of UK-listed Reckitt. The brand is headquartered in Parsippany, New Jersey, and serves general adult consumers, children, healthcare providers, and (since late 2025) Canadian consumers. The product portfolio spans extended-release bi-layer tablets containing guaifenesin (and dextromethorphan/phenylephrine variants in the DM and D lines), Fast-Max liquid gels and caplets for multi-symptom cold/flu relief, Sinus-Max nasal sprays with proprietary POWER-JET and GENTLE-MIST 2-in-1 nozzle technologies, Nightshift formulations for nighttime symptom relief, Rapid Clear caplets, and pediatric formulations under the Children's line, plus the recently launched Clear & Cool Saline Nasal Spray.

Mucinex's core technological differentiator is its extended-release bi-layer tablet platform, which delivers 12 hours of symptom relief per dose, roughly double the dosing interval of most generic competitors. The brand also maintains a significant clinical evidence base, including long-term findings from the GASP Study demonstrating efficacy of extended-release guaifenesin over 12 weeks in patients with stable chronic bronchitis. The brand has been supported for over two decades by the distinctive Mr. Mucus mascot, which functions as the principal intangible asset underpinning consumer recognition.

The business model is a classic OTC consumer health model: one-time retail purchases through mass retail distribution (pharmacies, grocery, mass merchants) in the US and Canada, supplemented by direct-to-consumer e-commerce via mucinex.com. Products are HSA/FSA eligible. The brand does not disclose its revenue separately; financial results are consolidated within Reckitt's Health segment. Marketing relies on a multi-channel approach including social media (Facebook, Instagram, YouTube), content marketing via a Tips & Resources learning center, public relations, and high-visibility experiential campaigns (e.g., the 2025 AR-enhanced 3D art installation at Grand Central Terminal with artist Kurt Wenner).

Mucinex firmographics

Firmographics
Name
Mucinex
Legal name
RB Health (US) LLC
Website
https://mucinex.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Mucinex is a US OTC consumer health brand owned by Reckitt, providing 12-hour extended-release cold, flu, sinus, and chest congestion relief products for general adults, children, and now Canadian consumers, distributed through major retailers and direct e-commerce.
Ownership category
akta.pro rank

Mucinex industry classification

Industry
Product category
OTC Cold, Flu & Sinus Medications
NAICS
Soap and Cleaning Compound Manufacturing (32561)
akta.pro industry
PRIMARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYHLAIADAB
Cold, Flu & Cough Remedies
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAL
Pediatric OTC Medicines
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • OTC cold and flu remedies
  • Extended-release expectorant tablets
  • Nasal decongestant sprays
  • Pediatric cough medications
  • Sore throat relief products

Where Mucinex is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mucinex business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Marketing or Sales, Supply Chain, Technology or R&D, Personnel

Revenue model

  1. OTC Pharmaceutical Products: Mucinex generates revenue through the sale of over-the-counter cold, flu, and sinus relief medications including extended-release tablets, liquid gels, caplets, and nasal sprays. Products are sold as one-time purchases through retail partners and direct-to-consumer e-commerce channels. HSA/FSA eligible expenses.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Mucinex product offering

Product offering

Core offering

Mucinex manufactures and sells over-the-counter cold, flu, sinus, cough, and sore throat medications for adults and children under the Mucinex brand umbrella. Its core technology is a 12-hour extended-release bi-layer tablet (guaifenesin-based), complemented by fast-acting liquid gels, caplets, nasal sprays with POWER-JET and GENTLE-MIST nozzle systems, and pediatric formulations. Products are sold as one-time purchases in retail stores and direct-to-consumer e-commerce.

Product overview

Mucinex is an over-the-counter (OTC) cold, flu, and sinus relief brand owned by Reckitt. The product portfolio is structured as a multi-format platform approach, offering medications in extended-release bi-layer tablets, fast-acting liquid gels/caplets, nasal sprays, and children's formulations. The core products include Mucinex Extended-Release Bi-Layer Tablets (the original guaifenesin-based chest congestion product), the Fast-Max line (liquids and caplets for multi-symptom cold and flu), Sinus-Max products (targeting sinus and nasal congestion including Clear & Cool nasal sprays), Nightshift formulations (specialized nighttime products for sleep-friendly symptom relief), Rapid Clear (rapid-release caplets), and children's variants. The products work together as a comprehensive symptom management system covering cough, chest congestion, sinus/nasal congestion, cold, flu, sore throat, and pain symptoms across different age groups and symptom severities.

Differentiator

Problem solved

Functional benefit

Brands

  • Fast-Max: Line of fast-acting liquid and gel cold and flu relief products
  • Sinus-Max
  • Nightshift
  • InstaSoothe
  • Rapid Clear
  • Children's Products

Products and services

  • Mucinex Extended-Release Bi-Layer Tablets Extended-release bi-layer tablets containing guaifenesin for chest congestion relief. Provides 12-hour symptom relief by thinning and loosening mucus in the airways. Targeted at adults with chest congestion.
  • Mucinex DM Extended-Release Bi-Layer Tablets Extended-release bi-layer tablets combining guaifenesin (expectorant) and dextromethorphan (cough suppressant) for chest congestion and cough relief over 12 hours. Targeted at adults with cough and chest congestion.
  • Maximum Strength Mucinex DM Extended-Release Bi-Layer Tablets Maximum strength version of extended-release bi-layer tablets combining guaifenesin and dextromethorphan for severe chest congestion and cough, providing 12-hour relief. Targeted at adults with severe cough and congestion.
  • Mucinex Fast-Max Liquid Products Fast-acting liquid and liquid gel formulations for multi-symptom cold and flu relief. Includes Day and Night formulas, severe cold variants, and combination packs. Targeted at adults needing multi-symptom cold and flu relief.
  • Mucinex Fast-Max Caplets Rapid-release caplet formulations for cold, flu, and congestion symptoms. Includes Day Cold & Flu, Night Cold & Flu, Severe Congestion & Cough, and Cold, Flu & Sore Throat variants. Targeted at adults with multi-symptom cold and flu.
  • Mucinex Sinus-Max Products Product line specifically targeting sinus symptoms including nasal sprays, liquid gels, caplets, and combination day/night packs. Includes Clear & Cool nasal spray with menthol cooling sensation. Targeted at adults with sinus and nasal congestion.
  • Sinus-Max Severe Nasal Congestion Relief Clear & Cool Nasal decongestant spray with oxymetazoline hydrochloride (0.05%) providing up to 12 hours of relief with a cooling menthol flavor. Fast-acting for day and night use. Targeted at adults with severe nasal congestion.
  • Mucinex Sinus-Max Saline Nasal Spray Drug-free saline nasal spray with 2-in-1 nozzle technology featuring POWER-JET for tough congestion (ages 6+) and GENTLE-MIST for everyday use (ages 2+). Targeted at adults and children with everyday nasal congestion.
  • Mucinex Sinus Clear & Cool Saline Nasal Spray Saline nasal spray with instant cooling sensation for congestion relief. Features dual spray settings — POWER-JET for tough congestion (ages 12+) and GENTLE-MIST for everyday use. Targeted at adults and older children with congestion seeking drug-free relief.
  • Mucinex Nightshift Products Nighttime-specific formulations for cold, flu, and sinus symptoms. Includes Nightshift Cold & Flu (liquid and caplets), Nightshift Sinus, and Nightshift Severe Cold & Flu variants. Designed to help users sleep and wake up feeling better. Targeted at adults whose symptoms disrupt sleep.
  • Mucinex Rapid Clear Products Rapid-release caplet line for fast symptom relief. Includes DayTime (Pain, Headache & Mucus Congestion) and NightTime (Headache, Cough & Fever) formulations, plus combination packs. Targeted at adults needing fast-acting relief.
  • Mucinex Children's Products Product line formulated for children including liquids, mini-melts, chewable tablets, and multi-symptom cold & flu formulations. Available in flavors such as Very Berry, Cherry, Mixed Berry, and Orange Creme. Targeted at parents/caregivers treating pediatric cough, congestion, and cold symptoms.
  • Mucinex InstaSoothe Products Sore throat relief line including Kickstart Sore Throat Spray (Winterfresh flavor), Sore Throat + Cough Relief, Sore Throat + Pain Relief (drops and spray), Soothing Comfort, and Sugar-Free Cough Drops (Mixed Berry). Targeted at adults with sore throat and cough symptoms.

Quantifiable outcome

  • 12-hour symptom relief duration from extended-release formulations
  • +2 more outcomes

Companies that use Mucinex

Customer profile

Segments4 records

Ideal customer profiles3 records

Mucinex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Mucinex partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Kurt WennerminorStrategic or Co-development Partner · 1 December 2025Mucinex partnered with artist Kurt Wenner to create an experiential 3D art exhibit at Grand Central Terminal (December 1-7, 2025). The glacier-inspired installation promoted the new Clear & Cool Sinus Nasal Spray with interactive AR elements, visually representing the product's cooling relief benefit.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Mucinex competitors and assessment

Company assessment

Direct peers

  • Robitussin: Robitussin (Haleon) is a direct OTC competitor offering cough, chest congestion, and multi-symptom cold/flu products (including DM formulations) targeting the same adult self-medication occasions as Mucinex's DM and Maximum Strength SKUs.
  • Tylenol Cold & Flu: Tylenol Cold & Flu (Kenvue / Johnson & Johnson) is a direct competitor in cold/flu multi-symptom relief, anchored by acetaminophen-based formulations. Tylenol's household-name brand and similar SKU structure make it one of Mucinex's closest OTC rivals on shelf.
  • Alka-Seltzer Plus: Alka-Seltzer Plus (Bayer) is a direct competitor offering effervescent and cold/flu multi-symptom formulations, addressing the same self-medication use cases and competing for the same cold/flu shelf space as Mucinex's Fast-Max line.
  • Sudafed: Sudafed (Kenvue) competes directly with Mucinex's Sinus-Max decongestant and pressure/pain SKUs in the nasal and sinus congestion category, using pseudoephedrine/phenylephrine-based formulations targeting the same adult consumer.
  • DayQuil / NyQuil: DayQuil and NyQuil (Procter & Gamble / Vicks franchise) are direct day/night multi-symptom cold and flu competitors. They share the same shelf positioning, retail channels, and adult consumer occasions as Mucinex's Fast-Max and Nightshift product lines.
  • Theraflu: Theraflu (Haleon) targets multi-symptom cold and flu relief through powdered and liquid formulations, directly competing with Mucinex Fast-Max in the same adult self-medication segment and same retail OTC shelves.
  • Vicks: Vicks (Procter & Gamble) competes across cough, cold, and sinus categories with VapoRub, NyQuil/DayQuil, and Sinex nasal sprays — overlapping Mucinex's chest congestion, multi-symptom, and sinus nasal spray lines with similar retail placement.

Emerging players

  • Benadryl: Benadryl (Kenvue) competes in adjacent OTC allergy/sinus categories that overlap with Mucinex's Sinus-Max line and overlap consumer occasions for multi-symptom relief, though Benadryl's core franchise is antihistamine-driven rather than expectorant.

Broad incumbents

  • Kenvue: Kenvue (spun out of Johnson & Johnson) owns Tylenol, Sudafed, Benadryl, Zyrtec, and Nicorette — a portfolio that directly overlaps Mucinex's cold/flu/sinus/allergy categories and competes for the same shelf, retailer relationships, and consumer occasions at global scale.
  • Haleon: Haleon is a global consumer health platform that owns Robitussin, Theraflu, Advil, Centrum, and Sensodyne, giving it broad OTC reach that includes direct Mucinex competitors. As Reckitt's closest peer in consumer health scale, Haleon represents the strategic benchmark for portfolio breadth and international reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Mucinex social profiles

Digital presence

Mucinex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mucinex leadership team

Management profile

Number of profiles

Mucinex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mucinex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mucinex

What does Mucinex do?

Mucinex manufactures and sells over-the-counter cold, flu, sinus, cough, and sore throat medications for adults and children under the Mucinex brand umbrella. Its core technology is a 12-hour extended-release bi-layer tablet (guaifenesin-based), complemented by fast-acting liquid gels, caplets, nasal sprays with POWER-JET and GENTLE-MIST nozzle systems, and pediatric formulations. Products are sold as one-time purchases in retail stores and direct-to-consumer e-commerce.

Is Mucinex a public or private company?

Mucinex is a private company. It is classified as corporate owned and is currently operating.

When was Mucinex founded?

Mucinex was founded in 2003. It employs 11 to 50 people.

Where is Mucinex based?

Mucinex is headquartered in New York, United States, in the North America region.

How does Mucinex make money?

One revenue line is on record: OTC Pharmaceutical Products.

Who are Mucinex's main competitors?

Direct peers on record are Robitussin, Tylenol Cold & Flu, Alka-Seltzer Plus, Sudafed, DayQuil / NyQuil, Theraflu and Vicks. Benadryl is listed as an emerging player. Broad incumbents are Kenvue and Haleon.

Does Mucinex have an API?

No public API is recorded for Mucinex.

What industry is Mucinex in?

Mucinex's product category is OTC Cold, Flu & Sinus Medications. Its primary akta.pro industry code is CRADAMAD, Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges), with a secondary code of HLAIADAB, Cold, Flu & Cough Remedies. Its NAICS code is 32561.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooDerek Hough speaks out on 'DWTS' lift rule and 'flawed' scoring | ExclusiveDerek Hough discussed his new Mucinex Recharge campaign and his views on DWTS scoring and lift rules. He called the scoring system flawed for using only whole numbers and said he is flexible on lift guidelines. He also emphasized his need for recovery time with his family.PR NewswireNEW MUCINEX® RECHARGE OFFERS POWERFUL, ALL-IN-ONE, NIGHTTIME COLD AND FLU SYMPTOM RELIEFMucinex launched Recharge, an all-in-one nighttime cold and flu relief product, and appointed Derek Hough as Chief Recharge Officer. The campaign highlights that 79% of American adults prioritize sleep when sick, aiming to help consumers recharge at night.Financial PostTalk Shop Unveils New Brand as Agency Continues North American GrowthTalk Shop announced a refreshed brand identity, new agency-of-record relationships, and three senior appointments. The agency expanded partnerships with Lavazza, JustFly, and Mucinex, and added roles including VP of Integrated and two senior directors. The cross-border team continues to grow in North America.PR NewswireMUCINEX® LAUNCHES GO ALL 12 CAMPAIGN TO POWER FANS THROUGH FOOTBALL SUNDAY, ALL SEASON LONGMucinex launched its 12-hour cold and fever multi-symptom product and a 'Go All 12' campaign, partnering with JoJo Fletcher and ESPN. The campaign includes a tailgate event, DoorDash delivery discounts, and in-store activations. The product delivers up to 12 hours of relief in one dose.NaverMucinex Go All 12 TailgateJoJo Fletcher attended the Mucinex "Go All 12" Tailgate in Tampa, FL, on Sept. 27, 2026, dodging Mr. Mucus and sharing how the new 12-hour cold and fever multi-symptom product helps relieve symptoms for a full 12 hours.NaverMucinex Go All 12 TailgateJoJo Fletcher attended the Mucinex "Go All 12" Tailgate in Tampa, FL, on Sept. 27, 2026, dodging Mr. Mucus and sharing how the new Mucinex 12HR Cold & Fever Multi-Symptom helps relieve cold and flu symptoms for a full 12 hours.EverydayHealth.com7 Best Doctor-Recommended OTC Cough SyrupsThis article presents a curated list of seven over-the-counter cough syrups recommended by board-certified physicians for various symptoms such as allergies, congestion, and nighttime relief. The recommendations cover specific brands including Benadryl, Robitussin, Delsym, Zarbee's, and Mucinex, detailing their active ingredients, target demographics, and key pros and cons. Medical experts advise on selecting the appropriate suppressant or expectorant based on cough type while highlighting safety considerations for children and potential drug interactions.MediaPostMucinex Chills Out In 3D At Grand Central StationReckitt's Mucinex brand launched its Clear and Cool Saline Nasal Spray with a 3D art installation in New York City's Grand Central Station running December 1-7, featuring a 20-foot glacial-themed mural by artist Kurt Wenner with AR components.PR NewswireMucinex + Artist Kurt Wenner to Debut Experiential 3D Art Exhibit in Grand Central Terminal - Week of 12/1Mucinex has partnered with artist Kurt Wenner to launch an experiential 3D art installation at Grand Central Terminal's Biltmore Room in New York, running December 1–7, 2025, to celebrate the debut of Mucinex Clear & Cool Sinus Nasal Spray. The glacier-inspired mural incorporates interactive AR elements and is designed to visually dramatize the cooling relief sensation of the new drug-free saline spray with menthol. Kurt Wenner, known for interactive 3D art illusions in over 30 countries, will be available for media interviews on December 1–2.PR NewswireMucinex® Introduces New Clear & Cool Sinus Nasal Spray, Delivering Instant Cooling Relief for CongestionMucinex, a Reckitt brand, launched its new Clear & Cool Saline Nasal Spray on November 20, 2025, expanding its respiratory health portfolio with a drug-free congestion relief solution. The spray features innovative 2-in-1 nozzle technology combining a Power-Jet setting for tough congestion with a gentle mist option, and is formulated with saline and menthol to deliver instant cooling relief. The product is now available at major U.S. retailers including Walgreens, CVS, and Walmart, with an immersive art installation planned for Grand Central Station in early December.